Acorda Therapeutics, Inc. (NASDAQ:ACOR)
| CAPS Rating |
|
|---|---|
| Open | $25.63 |
| Previous Close | $25.82 |
| Daily Range | $25.07 - $26.06 |
| 52-Week Range | $18.36 - $33.48 |
| Market Cap | $1.01B |
| P/E Ratio | 59.50 |
| Dividend (Yield) | N/A (N/A) |
| Volume | 625,435 |
| Average Daily Volume | 0 |
ACOR
VS S&P 500 (SPY)
How do you think ACOR will perform against the market?
Caps
Motley Fool CAPS is a community working together to find better stocks and to become better investors.
ACOR Advanced Details
- CAPS Community Analysis: Commentary, Scorecard
- Advanced Financial Analysis: Historical Prices, Chart, Stats, Ratios, Earnings/Growth Rates, Statements, SEC Filings
ACOR News and Commentary
- 3 Biotech Buyout Candidates for 2012 – The Motley Fool
- US Stock Futures: HOT STOCKS TO WATCH – SmartMoney
- Big Potential? Takeover Targets With Solid Profitability – NASDAQ
- Biogen Idec Passes This Key Test – The Motley Fool
- Modest Growth, Less-Than-Modest Stock Drop – The Motley Fool
- After Hours: Dendreon's Shares Crushed Again – The Motley Fool
- Invest in Biotechs Going After Unmet Needs – The Motley Fool
- Brain Disorders: 3 Biotech Stocks at the Forefront – NASDAQ
- Afternoon Roundup: Today's Top Stories – The Motley Fool
- Biogen, Acorda MS Drug Gets Conditional European Approval – SmartMoney
- PDL BioPharma: Dividend Dynamo or Blowup? – The Motley Fool
- 11 Stocks Breaking Down – Blog at The Motley Fool
- Acorda To Pay Up To $35 Million To Medtronic In Licensing Deal – SmartMoney
- Acorda Pushes Sales of MS Drug – Minyanville
- One Less Oral MS Drug to Worry About – The Motley Fool
- 3 Ways to Play Biotech With Options – The Motley Fool
- Options Ideas: 24 Healthcare Stocks With Bullish Options Sentiment – NASDAQ
- The Big Winner of the EU Drug Approval Bonanza – The Motley Fool
- Acorda Rises on European Surprise – Minyanville
- UPDATE: Biogen, Acorda MS Drug Gets EU Backing After Appeal – SmartMoney
RSS Headlines
Fool UK
